TABLE 2.
The chi-square test of the relation between risk score and clinical features in TCGA cohort.
| Clinical feature | Risk score |
c2 | p | |
| High risk n(%) | Low risk n(%) | |||
| Age | 0.037 | 0.848 | ||
| >65 | 72(59.02%) | 50(40.98%) | ||
| ≤65 | 124(57.94%) | 90(42.06%) | ||
| Gender | 3.244 | 0.072 | ||
| MALE | 126(55.02%) | 103(44.98%) | ||
| FEMALE | 70(65.42%) | 37(34.58%) | ||
| Histologic_grade | 4.543 | 0.033 | ||
| G1-2 | 112(53.59%) | 97(46.41%) | ||
| G3-4 | 80(65.57%) | 42(34.43%) | ||
| New_tumor_event_after_initial_treatment | 0.643 | 0.423 | ||
| YES | 98(59.76%) | 66(40.24%) | ||
| NO | 88(55.35%) | 71(44.65%) | ||
| Pathologic_stage | 3.703 | 0.054 | ||
| Stage I–II | 129(54.89%) | 106(45.11%) | ||
| Stage III–IV | 55(67.07%) | 27(32.93%) | ||
| Person_neoplasm_cancer_status | 2.846 | 0.092 | ||
| WITH TUMOR | 91(62.76%) | 54(37.24%) | ||
| TUMOR FREE | 94(53.41%) | 82(46.59%) | ||
| BMI | 0.566 | 0.452 | ||
| >25 | 82(55.03%) | 67(44.97%) | ||
| ≤25 | 96(59.26%) | 66(40.74%) | ||
| Race | 1.861 | 0.172 | ||
| White | 89(54.27%) | 75(45.73%) | ||
| Asian and others | 100(61.73%) | 62(38.27%) | ||
| Vascular tumor cell type | 6.887 | 0.009 | ||
| None | 94(51.09%) | 90(48.91%) | ||
| Micro-Macro | 66(67.35%) | 32(32.65%) | ||
| Prior_malignancy | 0.57 | 0.45 | ||
| No | 181(58.96%) | 126(41.04%) | ||
| Yes | 15(51.72%) | 14(48.28%) | ||